Our ambition is to have an impact beyond our investments
This year, World Cancer Day challenges each and every one of us to make an impact on Cancer.
We couldn't agree more. At Candriam, we launched our Oncology impact investing strategy in 2018 with the conviction that all of us have a role to play in the global fight against cancer. As investors, we can support cancer research and treatment.
Because our ambition is to have an impact beyond our investments, Candriam donates part of its revenues to various cancer research institutes. Candriam has contributed over €450,000 just for 2020. So that your investments will help fight cancer twice.
Oncololgy investing at Candriam: facts & figures1
- 3 years of Impact Investing
- USD 2 000 million in assets
- A team of 5 portfolio managers and analysts with an average of 10 years of experience
- • + 89% performance vs 70% for its benchmark the MSCI World for three years ending Dec 20212
- A fund registered in 12 countries
- 254 institutional investors and distributors who have subscribed a net USD 1,939 million
- More than 10 institutes and foundations supported through some 450 000€ of donations in 2020 and with a greater amount planned for 2021.
Invested capital and performance are not guaranteed and there is a risk of capital loss. The net asset value of the Fund may decrease, and is exposed to the following risks in particular: capital loss risk, equity risk.
1 Data as at end of 31.12.2021
2 Performance of the C share class of Candriam Equities L Oncology. Three years, Fund +88.9% vs Benchmark MSCI +69.8%. Past Performances are not an indicator of future performances and are not constant over time. The fund is managed actively, with reference to MSCI World NR. For further information about this index and its use, please consult the fund’s key investor information document (KIID).
-
Our oncology expertise